Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
Alector (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on neurodegeneration therapies, will host its Q2 2025 earnings conference call on Thursday, August 7, 2025, at 4:30 p.m. ET.
The call will feature Dr. Ryan Darby, Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will discuss unmet needs in frontotemporal dementia. The company will release its Q2 2025 financial results before the call.
Participants can access the webcast through Alector's investor relations website, with a 30-day replay available afterward. Phone participants must register online to receive dial-in details.
Alector (NASDAQ:ALEC), una società biotecnologica in fase avanzata focalizzata sulle terapie per le neurodegenerazioni, terrà la sua conference call sui risultati del secondo trimestre 2025 giovedì 7 agosto 2025 alle 16:30 ET.
La chiamata vedrà la partecipazione del Dott. Ryan Darby, Professore Associato di Neurologia e Direttore della Clinica per la Demenza Frontotemporale presso il Vanderbilt University Medical Center, che discuterà delle esigenze insoddisfatte nella demenza frontotemporale. La società pubblicherà i risultati finanziari del secondo trimestre 2025 prima della chiamata.
I partecipanti potranno seguire la webcast tramite il sito web delle relazioni con gli investitori di Alector, con una replica disponibile per 30 giorni. Chi partecipa telefonicamente deve registrarsi online per ricevere i dettagli di accesso.
Alector (NASDAQ:ALEC), una empresa biotecnológica en etapa avanzada centrada en terapias para neurodegeneración, realizará su conferencia telefónica de resultados del segundo trimestre de 2025 el jueves 7 de agosto de 2025 a las 4:30 p.m. ET.
La llamada contará con la participación del Dr. Ryan Darby, Profesor Asociado de Neurología y Director de la Clínica de Demencia Frontotemporal en el Centro Médico de la Universidad de Vanderbilt, quien hablará sobre las necesidades no cubiertas en la demencia frontotemporal. La empresa publicará los resultados financieros del segundo trimestre de 2025 antes de la llamada.
Los participantes podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Alector, con una repetición disponible durante 30 días después. Los participantes telefónicos deben registrarse en línea para recibir los detalles de acceso.
Alector (NASDAQ:ALEC)는 신경퇴행성 질환 치료제에 중점을 둔 후기 임상 단계의 생명공학 회사로, 2025년 8월 7일 목요일 오후 4시 30분(동부시간)에 2025년 2분기 실적 컨퍼런스 콜을 개최합니다.
이번 콜에는 Vanderbilt 대학 의료센터의 신경학 부교수이자 전측두엽 치매 클리닉 디렉터인 라이언 다비 박사가 참석하여 전측두엽 치매의 미충족 수요에 대해 논의할 예정입니다. 회사는 콜 전에 2025년 2분기 재무 결과를 발표할 예정입니다.
참가자들은 Alector 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 이후 30일간 다시보기 서비스를 이용할 수 있습니다. 전화 참가자는 온라인 등록을 통해 전화 접속 정보를 받아야 합니다.
Alector (NASDAQ:ALEC), une entreprise biotechnologique en phase avancée axée sur les thérapies contre la neurodégénérescence, organisera sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le jeudi 7 août 2025 à 16h30 ET.
La conférence accueillera le Dr Ryan Darby, professeur associé de neurologie et directeur de la clinique de démence frontotemporale au Vanderbilt University Medical Center, qui discutera des besoins non satisfaits dans la démence frontotemporale. La société publiera ses résultats financiers du deuxième trimestre 2025 avant la conférence.
Les participants pourront accéder au webcast via le site des relations investisseurs d'Alector, avec une rediffusion disponible pendant 30 jours après. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les informations d'accès.
Alector (NASDAQ:ALEC), ein biotechnologisches Unternehmen in der späten klinischen Phase mit Fokus auf Therapien gegen Neurodegeneration, wird seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 am Donnerstag, den 7. August 2025, um 16:30 Uhr ET abhalten.
Die Konferenz wird Dr. Ryan Darby, außerordentlicher Professor für Neurologie und Leiter der Frontotemporalen Demenzklinik am Vanderbilt University Medical Center, beinhalten, der über die ungedeckten Bedürfnisse bei frontotemporaler Demenz sprechen wird. Das Unternehmen wird die Finanzergebnisse für das zweite Quartal 2025 vor der Konferenz veröffentlichen.
Teilnehmer können den Webcast über die Investor-Relations-Website von Alector verfolgen, mit einer 30-tägigen Wiederholung danach. Telefonische Teilnehmer müssen sich online registrieren, um die Einwahldaten zu erhalten.
- None.
- None.
Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release detailing second quarter results will be issued prior to the call.
The event will be webcast live under the investor relations section of Alector’s website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
When is Alector's (ALEC) Q2 2025 earnings call scheduled?
Who is the guest speaker at Alector's Q2 2025 earnings call?
How can investors access Alector's Q2 2025 earnings call?
How long will the replay of Alector's Q2 2025 earnings call be available?
